Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
26 hedge funds and large institutions have $1.94M invested in Titan Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
24% more funds holding
Funds holding: 21 → 26 (+5)
0% more ownership
Funds ownership: 0% → 0% (+0%)
27% less capital invested
Capital invested by funds: $2.65M → $1.94M (-$707K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.15M |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$905K |
| 3 |
AC
Armistice Capital
New York
|
+$166K |
| 4 |
Renaissance Technologies
New York
|
+$43.5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$48K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$22K |
| 3 |
WPA
Winning Points Advisors
Boca Raton,
Florida
|
-$10.9K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$3K |
| 5 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WS
26
Wedbush Securities
Los Angeles,
California
| – | -$22K | -6 | Closed |
|
|
27
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$3K | -1 | Closed |
|
|
28
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$1K | – | – |
|
TTNP Hedge Fund Activity: Q3 2018 in Review
26 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q3 2018, worth a combined $1.94M — down 27% from $2.65M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TTNP positions and 3 closed out — a net gain of 5 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.15M. The largest seller was Millennium Management, exiting entirely with an estimated $48K sold.
- 26 institutional investors held Titan Pharmaceuticals (TTNP) as of Q3 2018, up from 21 in Q2 2018.
- Funds reported $1.94M of Titan Pharmaceuticals stock for Q3 2018, down 27% quarter-over-quarter.
- 8 funds opened new Titan Pharmaceuticals positions in Q3 2018 and 3 closed out, a net change of +5 holders.
- The largest Titan Pharmaceuticals buyer in Q3 2018 was Sabby Management, an estimated $1.15M added.
- The largest Titan Pharmaceuticals seller in Q3 2018 was Millennium Management, an estimated $48K sold.
Based on aggregated 13F filings for Q3 2018.